Harbin Pharmaceutical Group Co (SHSE:600664) FFO


SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
78 GF Score
Price ¥3.14
GF Value ¥3.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:600664
78GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥3.14 is trading 10.5% below its estimated GF Value™ of ¥3.51. GuruFocus considers Harbin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:600664:

  • FFO:
  • GF Value™: ¥3.51 vs. price of ¥3.14 (10.5% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
78GF Score

Get the complete analysis for SHSE:600664

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.14
Price
¥3.51
GF Value